Companies · AI / ML
HOUSTON · AI / ML · refined from filed group “Other Health Care” · https://clinigencehealth.com/
Diligence memoA one-page analyst read on Clinigence Holdings, Inc. — recommendation, valuation, rhythm, risks.→Clinigence Holdings, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the ai/ml sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Clinigence Holdings, Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Clinigence Holdings, Inc. is one of 2067 AI / ML companies tracked from HOUSTON. By capital raised it ranks among the largest (ahead of 100% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Discover the advanced analytics-driven solution for payers and provider organizations - Clinigence Health software.
Discover the advanced analytics-driven solution for payers and provider organizations - Clinigence Health software. Discover the advanced business intelligent software solution that turns your data into useful insights for the health care ecosystem to enhance value-based care through generative AI. Developed with the success of the end user in mind. The QMX® provides: Discover how Clinigence Health Makes a Difference Today
Trades publicly as Clinigence Health.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series C, Series D+ — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 57%.
Round size and date are reported; the stage label is inferred from round size (latest is Growth/Late — a round over $400M). Valuation is modeled from stage benchmarks scaled by the ai/ml sector profile. Directional, not a quoted figure.
Benchmarked against 2067 companies in AI / ML. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 100% of sector peers (real $). Modeled value above 86% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Growth/Late) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #4 of 5.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| CoreWeave, Inc. | Growth/Late | $1.2B | $17.7B | 2.76× |
| SMG Aggregator, LLC | Growth/Late | $601.7M | $10.9B | 1.70× |
| Figma, Inc. | Growth/Late | $715.5M | $6.4B | 1.00× |
| Clinigence Holdings, Inc. this company | Growth/Late | $2.5B | $56.0M | 0.01× |
| Envisionit Deep AI | Growth/Late | $1.6M | $34.9M | 0.01× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $8.8M | 2018-07-01 | $39.8M | $316.2M | 90% |
| Series A | $3.1M | 2018-10-24 | $14.2M | $112.6M | 90% |
| Series B | $15.7M | 2019-03-21 | $87.2M | $622.6M | 90% |
| Series B | $2.3M | 2019-10-24 | $13.0M | $93.0M | 90% |
| Series B | $24.5M | 2019-10-29 | $136.1M | $971.6M | 90% |
| Series B | $24.5M | 2019-10-29 | $136.1M | $971.6M | 90% |
| Series B | $32.0M | 2021-03-02 | $177.6M | $974.4M | 90% |
| Series B | $11.3M | 2021-05-14 | $62.9M | $318.9M | 90% |
| Seed | $1.9M | 2021-05-14 | $9.6M | $54.4M | 90% |
| Growth/Late | $2.4B | 2022-04-01 | $23.7B | $63.6B | 90% |
| Growth/Late | $3.1M | 2023-09-30 | $30.9M | $56.0M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| MICHAEL CHANG | — | 12 other | 2022-04 |
| Matthew Young | — | 6 other | 2022-04 |
| Mihir Shah | — | 6 other | 2018-10 |
| Michael Bowen | — | 5 other | 2021-03 |
| Warren Hosseinion | — | 3 other | 2018-10 |
| Elisa Luqman | — | 2 other | 2021-03 |
| Warren Hosseinionn | — | 2 other | 2023-09 |
| John Waters | — | 1 other | 2019-10 |
| Lawrence Schimmel | — | 1 other | 2018-10 |
| Mark Fawcett | — | 1 other | 2021-05 |
| Martin Breslin | — | 1 other | 2018-10 |
| Michael Reed | — | 1 other | 2022-04 |
| Richard Chan | — | 1 other | 2021-03 |
| Andrew Barnett | — | — | 2021-03 |
| Brandon Sims | — | — | 2021-05 |
| Charles Kandzierski | — | — | 2018-10 |
| Cheryl Grenas | — | — | 2022-04 |
| Danniel Stites | — | — | 2023-09 |
| David Martin Meiri | — | — | 2019-10 |
| David Meiri | — | — | 2018-10 |
| Denise Pufal | — | — | 2022-04 |
| Elisa Martin Luqman | — | — | 2019-10 |
| Fred Sternberg | — | — | 2021-03 |
| Hosseinion Warren | — | — | 2021-05 |
Clinigence Holdings, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Apollo Medical Holdings, Inc. | Healthtech | Series D+ | $312.8M | $11.2M | network3 shared operators |
| Vesicor Therapeutics, Inc. | Biotechnology | Pre-Seed | $715K | $2.4M | network3 shared operators |
| Hera Topco, Inc. | Other | Growth/Late | $462.7M | $7.2B | network1 shared operator · same stage |
| Cardio Diagnostics Inc. | Biotechnology | Series A | $13.2M | $94.2M | network2 shared operators |
| Qualmetrix, Inc. | Other Health Care | Series A | $6.1M | $100.9M | network2 shared operators |
| Envisionit Deep AI | AI / ML | Growth/Late | $1.6M | $34.9M | same sector · same stage |
| Cardio Diagnostics Holdings, Inc. | Biotechnology | Pre-Seed | $1.0M | $6.0M | network2 shared operators |
| Tiny Ltd. | AI / ML | Series C | $73.8M | $14.5M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| DOC.AI Inc | AI / ML | Seed | $101.0M | 79% |
| ThinkBio.Ai, Inc | AI / ML | Pre-Seed | $4.5M | 77% |
| Cygnus-AI Inc. | AI / ML | Pre-Seed | $29.2M | 77% |
| Clarion The AI communication layer for healthcare | Healthtech | — | — | 77% |
| Neural Analytics, Inc. | AI / ML | Series B | $258.0M | 77% |
| Cohort Intelligence Corp | AI / ML | Series A | $342.0M | 76% |
| Lilia Ai, Inc. | AI / ML | Seed | $4.6M | 76% |
| Healwell AI Inc. | AI / ML | Seed | $9.9M | 76% |
See where Clinigence Holdings, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Clinigence Holdings, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.